Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
2.830
-0.400 (-12.38%)
At close: Dec 24, 2025, 1:00 PM EST
2.880
+0.050 (1.77%)
After-hours: Dec 24, 2025, 4:59 PM EST
Biodexa Pharmaceuticals Employees
Biodexa Pharmaceuticals had 13 employees as of December 31, 2024. The number of employees decreased by 8 or -38.10% compared to the previous year.
Employees
13
Change (1Y)
-8
Growth (1Y)
-38.10%
Revenue / Employee
n/a
Profits / Employee
-$656,254
Market Cap
1.75M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | -8 | -38.10% |
| Dec 31, 2023 | 21 | -6 | -22.22% |
| Dec 31, 2022 | 27 | 7 | 35.00% |
| Dec 31, 2021 | 20 | 2 | 11.11% |
| Dec 31, 2020 | 18 | -47 | -72.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BDRX News
- 7 days ago - Biodexa Announces Pricing of $10 Million Public Offering - GlobeNewsWire
- 24 days ago - Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP - GlobeNewsWire
- 4 weeks ago - Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP - GlobeNewsWire
- 7 weeks ago - Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion - GlobeNewsWire
- 2 months ago - Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025 - GlobeNewsWire
- 3 months ago - Interim results for the six months ended June 30, 2025 - GlobeNewsWire
- 3 months ago - Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled - Accesswire
- 4 months ago - Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewsWire